Pyrazolam

Pyrazolam is a synthetic triazolobenzodiazepine developed by Hoffmann-La Roche in the late 1970s. It was never marketed as a medicine and later appeared on the research-chemical market. User reports describe it as primarily anxiolytic, with less emphasis on euphoria than many other designer benzodiazepines. Direct pharmacological data remain limited, although its metabolism and forensic detection have been studied.

Chemistry and history

Pyrazolam has a triazolobenzodiazepine structure related to alprazolam. It differs by having a bromine substituent and a pyridinyl group in place of the phenyl group found in many other benzodiazepines. The compound was first identified in a seizure of tablets by Finnish Customs in 2011 and was subsequently reported to the European Early Warning System in 2012.

Pharmacology

Pyrazolam is expected to act at the benzodiazepine site of the GABA_A receptor, enhancing the effect of GABA. However, a detailed receptor-binding and functional profile has not been established. Much of the early pharmacological description was inferred from its structure and from user reports.

A review of online experience reports found that pyrazolam was described as one of the more anxiolytic designer benzodiazepines, with relatively little euphoria. The authors emphasised that these reports are not equivalent to controlled clinical observations (Designer benzodiazepines’ pharmacological effects and potencies, 2020).

Metabolism

Human urine studies have identified several pyrazolam metabolites and proposed markers for forensic detection. A 2018 study examined urine samples from confirmed cases and characterised the metabolic pattern using high-resolution mass spectrometry. The findings helped establish analytical targets for detecting pyrazolam exposure (Bergstrand and colleagues, 2018).

Subjective effects

The PsychonautWiki profile of pyrazolam describes anxiety relief characteristic of benzodiazepines. User accounts emphasise reduced anxiety and sedation more than euphoria, in contrast to reports about some other designer benzodiazepines.

Physical effects

Reported effects include relaxation, reduced muscle tension and drowsiness. Some users describe a relatively clear-headed effect, but this does not mean that coordination or reaction time are unaffected. The available reports are too limited to determine how consistent this distinction is.

Cognitive effects

Anxiety reduction is the main reported psychological effect. Disinhibition and memory impairment may also occur, particularly when the sedative effects become more pronounced. User reports do not establish a reliable frequency for amnesia or other cognitive effects.

Clinical and forensic findings

Pyrazolam has been detected in urine samples from routine drug testing and emergency-department investigations. In one analytical study of 126 samples that had screened positive for benzodiazepines but were negative for commonly tested prescription drugs, pyrazolam was among the novel benzodiazepines identified (Urine analysis of 28 designer benzodiazepines, 2018).

A 2026 case report described acute pyrazolam poisoning in a patient who had consumed a mixture containing alcohol, pyrazolam, methadone and other psychoactive substances. The case demonstrates the difficulty of interpreting mixed-drug intoxication and the value of high-resolution mass spectrometry, but it does not isolate the effects of pyrazolam alone (Magny and colleagues, 2026).

Dependence and safety

There are no controlled studies that quantify pyrazolam dependence or withdrawal. Its activity at the benzodiazepine site makes tolerance and physical dependence plausible, as with other drugs in the class. Combining it with opioids, alcohol or other sedatives can increase central nervous system depression. Abrupt cessation after regular use may cause serious withdrawal, including seizures.

Related compounds

Pyrazolam is related to Alprazolam, Clonazolam and other triazolobenzodiazepines. Its pyridinyl group and bromine substituent distinguish it from the more familiar members of this group.